🇺🇸 FDA
Pipeline program

DC-CIK Immunotherapy

CZ1H-BC-001

Phase 2 mab active

Quick answer

DC-CIK Immunotherapy for Breast Cancer is a Phase 2 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Breast Cancer
Phase
Phase 2
Modality
mab
Status
active

Clinical trials